2024 ASCO Annual Meeting: Merus N.V. presents updated interim data on MCLA-145, showing manageable safety profile and early clinical activity in difficult-to-treat cancers.
Merus N.V. announced updated interim data on MCLA-145 monotherapy and in combination with pembrolizumab at the 2024 ASCO Annual Meeting. MCLA-145 showed a manageable safety profile and early clinical activity in difficult-to-treat cancers. Biomarker data suggest that dose and less frequent administration may impact clinical activity, and Merus is encouraged by the progress made with MCLA-145.
June 02, 2024
3 Articles